CNCE

CTP-692

Schizophrenia

Stage (next event)

Expected Date

Phase 2 Topline Data

Q1 2021

Catalyst Info & Data Links

TITLE: CTP-692 for Schizophrenia - Phase 2 

  • ClinicalTrial.gov (NCT04158687): A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-692 as an Adjunctive Treatment in Adults With Schizophrenia


WHAT IS THE NEXT CATALYST EVENT?

  • CTP-692 Topline Data


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?

  • Q1 2020


PRIOR DATA

PRESS RELEASES

Mechanism of Action

MECHANISM OF ACTION

  • CTP-692 is a deuterium-modified analog of the endogenous NMDA receptor co-agonist, D-serine. Based on documented effects of D-serine, the Company believes that CTP-692 has the potential to restore NMDA receptor activity in key areas of the brain in patients with schizophrenia. 

Updated by JM 

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See what the community is saying - click to see full post

Incyte (INCY) appears to have the stronger hand in its patent disputes with Concert (CNCE), regardle

Incyte (INCY) appears to have the stronger hand in its patent disputes with Concert (CNCE), regardle

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon